New report shows dramatic rise in medical technology, pharmaceuticals and healthcare costs

Management of Emerging Healthcare Solutions, Inc. (Pinksheets: EHSI) stated that they were encouraged by a new report that parallels the company’s conclusions about the new potential for business in the current healthcare marketplace. The report on US health trends, released yesterday by the Centers for Disease Control and Prevention National Center for Health Statistics, showed a sharp increase in the use of medical technology and pharmaceuticals between 1996 and 2007. The report also reflected that health costs to treat individuals tripled between 1990 and 2007.

Among the findings: The rate of advanced diagnostic imaging tests tripled between 1996 and 2007. The use of advanced diagnostic tests in the emergency room increased fivefold in adults under 65 and quadrupled among adults 65 or older. Among people over 45, use of drugs to treat diabetes rose 50 percent between 2003 and 2006. Also, during the same period, use of cholesterol-lowering statin drugs increased tenfold among people 45 and older

With the Democratic Senate falling under a filibuster-proof majority and mid-term Congressional elections approaching, many feel that any meaningful health care cost controlling legislation is unrealistic – especially in light of a proposed Republican strategy to filibuster all initiatives leading up to the mid-term elections. In light of this, healthcare investment is seen by many to be a place for potentially high gains as opposed to other lackluster opportunities.

Accordingly, the ongoing healthcare industry boon could be beneficial to many sector players such as Eli Lilly & Co. (NYSE: LLY), GlaxoSmithKline Plc (NYSE: GSK), Quest Diagnostics (NYSE: DGX) and Pharmaceutical Product Development, Inc. (NASDAQ: PPDI).